摘要
目前我国创新药物临床试验中针对出现的不良事件没有可以遵循的相关法律法规,尚未形成统一的赔付标准。本研究选取国家科技重大专项"创新药物临床评价技术平台"课题中标单位为调研对象,探讨建立创新药物临床不良事件赔付机制和实现赔付机制的途径、方式和方法。
Because lack of the law and unified compensation standards about compensation of innovation drug adverse event in China, the sufferers cannot get any compensation from the correlative responsibility party. By choosing the ‘Significant Innovation Drugs Creation’ bid units , this research carry out survey to find out and discuss the optimization approach to establish innovation drug adverse event compensation system.
出处
《中国医院》
2015年第6期13-15,共3页
Chinese Hospitals
基金
国家科技重大专项创新药物临床评价技术平台(2008ZX09312-008)
关键词
药物临床试验
伤害赔付
drug clinical trail
damage and compensation
